Literature DB >> 24611771

Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy.

Yusuf Yilmaz1, Atakan Yesil, Fatma Gerin, Rabia Ergelen, Hakan Akin, Çigdem Ataizi Celikel, Nese Imeryuz.   

Abstract

OBJECTIVE: Measurements of controlled attenuation parameter (CAP) with transient elastography (FibroScan®; EcoSens SA, Paris, France) may provide an accurate noninvasive assessment of hepatic steatosis. Herein, we prospectively determined the accuracy of liver fat quantification with CAP values in patients with chronic liver diseases and compare the results with those of histological assessment of steatosis as reference standard.
MATERIALS AND METHODS: We enrolled 50 Turkish patients with various forms of chronic liver diseases. All patients underwent both CAP assessment and ultrasonography-guided liver biopsy.
RESULTS: On liver biopsy, 16 (32%) patients had S0, 12 (24%) had S1, 9 (18%) had S2, and 13 (26%) had S3. The CAP values increased significantly (p<0.001) for each steatosis stage on liver biopsy: S0, 222 dB/m; S1, 250 dB/m; S2, 270 dB/m; and S3, 318 dB/m. A cutoff value of 257 dB/m could distinguish significant steatosis (S2-S3) from S0 (Sn 89%, Sp 83%, positive likelihood ratio 5.33, negative likelihood ratio 0.13, AUROC=0.93). Multivariable analysis indicated that neither liver fibrosis (p=0.58) nor disease etiology (p=0.96) had a significant impact on the association between CAP and the stage of steatosis.
CONCLUSION: The determination of CAP using transient elastography can represent an important step forward toward the goal of an "imaging liver biopsy".

Entities:  

Mesh:

Year:  2014        PMID: 24611771     DOI: 10.3109/00365521.2014.881548

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  11 in total

1.  Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis.

Authors:  Razan M Bader; Maureen M Jonas; Paul D Mitchell; Shanna Wiggins; Christine K Lee
Journal:  J Cyst Fibros       Date:  2018-12-01       Impact factor: 5.482

2.  Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population.

Authors:  Wah-Kheong Chan; Nik Raihan Nik Mustapha; Grace Lai-Hung Wong; Vincent Wai-Sun Wong; Sanjiv Mahadeva
Journal:  United European Gastroenterol J       Date:  2016-06-23       Impact factor: 4.623

3.  Normal controlled attenuation parameter values: a prospective study of healthy subjects undergoing health checkups and liver donors in Korea.

Authors:  Young Eun Chon; Kyu Sik Jung; Kwang Joon Kim; Dong Jin Joo; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Seung Up Kim
Journal:  Dig Dis Sci       Date:  2014-08-14       Impact factor: 3.199

4.  Usefulness of liver test and controlled attenuation parameter in detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease.

Authors:  Ivana Mikolasevic; Lidija Orlic; Luka Zaputovic; Sanjin Racki; Zlatko Cubranic; Kata Anic; Bosiljka Devcic; Davor Stimac
Journal:  Wien Klin Wochenschr       Date:  2015-04-09       Impact factor: 1.704

Review 5.  Non-invasive diagnosis of hepatic steatosis.

Authors:  Christiane Stern; Laurent Castera
Journal:  Hepatol Int       Date:  2016-10-25       Impact factor: 6.047

Review 6.  Non-alcoholic fatty liver disease: A growing public health problem in Turkey.

Authors:  Eda Kaya; Yusuf Yılmaz
Journal:  Turk J Gastroenterol       Date:  2019-10       Impact factor: 1.852

7.  Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease.

Authors:  Chan-Young Jung; Geun Woo Ryu; Hyung Woo Kim; Sang Hoon Ahn; Seung Up Kim; Beom Seok Kim
Journal:  Diabetologia       Date:  2021-12-21       Impact factor: 10.122

8.  Comparison of Controlled Attenuation Parameter and Liver Biopsy to Assess Hepatic Steatosis in Pediatric Patients.

Authors:  Nirav K Desai; Sarah Harney; Roshan Raza; Alyaa Al-Ibraheemi; Nick Shillingford; Paul D Mitchell; Maureen M Jonas
Journal:  J Pediatr       Date:  2016-03-30       Impact factor: 4.406

9.  Comparing different non-invasive methods in assessment of the effects of curcumin on hepatic fibrosis in patients with non-alcoholic fatty liver disease.

Authors:  Saeede Saadati; Azita Hekmatdoost; Behzad Hatami; Asieh Mansour; Zahra Zahra; Mehdi Hedayati; Amir Sadeghi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2018

10.  Quantitative ultrasound, elastography, and machine learning for assessment of steatosis, inflammation, and fibrosis in chronic liver disease.

Authors:  François Destrempes; Marc Gesnik; Boris Chayer; Marie-Hélène Roy-Cardinal; Damien Olivié; Jeanne-Marie Giard; Giada Sebastiani; Bich N Nguyen; Guy Cloutier; An Tang
Journal:  PLoS One       Date:  2022-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.